Amylyx Pharmaceuticals, Inc.

AMLX · Nasdaq · United States

Share price · AMLX

$26.62-8.49 (-24.18%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.5M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AMLX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Nov 2026-8.2%

    Nothing announced by AMLX that day or the session before.

  2. 18 Aug 2026+63.8%
  3. 7 Aug 2026-5.7%
  4. 6 Aug 2026+10.7%
  5. 4 Aug 2026+8.4%

    Nothing announced by AMLX that day or the session before.

  6. 27 Jul 2026+5.9%

    Nothing announced by AMLX that day or the session before.

  7. 24 Jul 2026+4.7%

    Nothing announced by AMLX that day or the session before.

  8. 14 Jul 2026+4.5%

    Nothing announced by AMLX that day or the session before.

  9. 4 Jun 2026+8.4%
  10. 20 Jan 2026+15.7%

    Nothing announced by AMLX that day or the session before.

Share of unusual movement by asset

For each asset, the share of AMLX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
avexitide
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—30%
Other company news (earnings, financing, releases naming no asset)—15%
Sessions with no dated event—55%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
GLP-1 receptor (antagonist)Peptide
Hyperinsulinemic Hypoglycemia
Post-Bariatric Hypoglycemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 August 2026Topline resultavexitideLUCIDITY Phase 3 (NCT06747468) meets primary endpoint
Amylyx Pharmaceuticals, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$28M$240M+ $528M short-term inv.$45M-$34M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$24M$49M+ $201M short-term inv.$43M-$31M operating cash flowreport ↗
2026-Q1—$28M$229M+ $51M short-term inv.$41M-$37M operating cash flowreport ↗
2025-Q3$0$20M$225M+ $119M short-term inv.$34M-$30M operating cash flowreport ↗
2025-Q2$0$27M$58M+ $123M short-term inv.$41M-$25M operating cash flowreport ↗
2025-Q1$0$22M$60M+ $144M short-term inv.$36M-$40M operating cash flowreport ↗
2024-Q3$0.4M$21M$72M+ $163M short-term inv.$73M-$42M operating cash flowreport ↗
2024-Q2-$1.0M$23M$75M+ $235M short-term inv.$73M-$67M operating cash flowreport ↗
2024-Q1$89M$37M$171M+ $203M short-term inv.$119M-$0.5M operating cash flowreport ↗
2023-Q3$103M$30M$135M+ $220M short-term inv.—-$5.2M operating cash flowreport ↗
2023-Q2$98M$29M$248M+ $110M short-term inv.—$8.6M operating cash flowreport ↗
2023-Q1$71M$24M$115M+ $231M short-term inv.—-$5.1M operating cash flowreport ↗
2022-Q3$0.3M$25M$108M+ $55M short-term inv.$54M-$43M operating cash flowreport ↗
2022-Q2—$24M$67M+ $139M short-term inv.$54M-$46M operating cash flowreport ↗
2022-Q1—$21M$110M+ $145M short-term inv.$48M-$41M operating cash flowreport ↗
2021-Q3—$13M—$23Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$90M$227M+ $90M short-term inv.$36M-$123M operating cash flowreport ↗

Amylyx Pharmaceuticals reported full-year 2025 revenue of $0M, down 100.0% YoY, with R&D spend of $90.4M, down 13.1% YoY. The company held cash and equivalents of $226.65M and posted a net loss of $144.74M.

Management guided to a cash runway into 2028. Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia is complete, with topline data expected in Q3 2026 and potential commercialization in 2027 if approved. The company also presented early safety data from Cohort 1 of the Phase 1 LUMINA trial of AMX0114 in ALS, expects Cohort 2 enrollment completion in March 2026, and selected AMX0318 as a development candidate with an IND filing targeted for 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$87M$104M$77M+ $99M short-term inv.$75M-$168M operating cash flowreport ↗
2023-FY$381M$128M$170M+ $201M short-term inv.—$12M operating cash flowreport ↗
2022-FY$22M$93M$63M+ $284M short-term inv.$50M-$180M operating cash flowreport ↗
2021-FY—$44M$50M+ $46M short-term inv.$22M-$75M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($152K), 39 sales ($17.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-10FRATES JAMES M · Chief Financial OfficerOption exercise20,000$6.88$138KForm 4
2026-11-10FRATES JAMES M · Chief Financial OfficerOpen-market sale12,800$30.32$388KForm 4
2026-11-10FRATES JAMES M · Chief Financial OfficerOpen-market sale7,200$30.97$223KForm 4
2026-11-10FRATES JAMES M · Chief Financial OfficerOption exercise (derivative)20,000——Form 4
2026-11-09Cohen Joshua B · director, Co-Chief Executive OfficerOpen-market sale38,105$29.39$1.1MForm 4
2026-11-09Klee Justin B. · director, Co-Chief Executive OfficerOpen-market sale37,483$29.39$1.1MForm 4
2026-11-09FRATES JAMES M · Chief Financial OfficerOption exercise20,000$6.88$138KForm 4
2026-11-09Cohen Joshua B · director, Co-Chief Executive OfficerOpen-market sale61,895$30.11$1.9MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 171 reporting institutions held 114.8M shares ($1.6B, 89.3% of shares outstanding).

#InstitutionSharesValue
1FMR LLC16,630,541$231.2M
2BlackRock, Inc.8,828,836$122.7M
3PERCEPTIVE ADVISORS LLC8,284,882$115.2M
4TCG Crossover Management, LLC6,243,812$86.8M
5Commodore Capital LP5,650,000$78.5M
6JANUS HENDERSON GROUP PLC4,986,073$69.3M
7Saturn V Capital Management LP4,349,885$60.5M
8VANGUARD CAPITAL MANAGEMENT LLC4,141,575$57.6M
9ADAGE CAPITAL PARTNERS GP, L.L.C.3,560,764$49.5M
10First Light Asset Management, LLC3,190,645$44.3M
11Driehaus Capital Management LLC2,987,147$41.5M
12GOLDMAN SACHS GROUP INC2,625,991$36.5M
13STATE STREET CORP2,363,161$32.8M
14FRANKLIN RESOURCES INC2,261,569$31.4M
15GEODE CAPITAL MANAGEMENT, LLC2,210,932$30.7M